Navigation Links
Masimo Initiates Full Market Release of First-Ever Noninvasive Continuous Hemoglobin Monitor
Date:3/24/2009

ction 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our belief that the commercial availability of SpHb technology and products will serve to increase adoption, market share and/or revenues for the company, risks that limited market release clinical results may not be duplicated in the full market launch, risks related to our assumption that SpHb technology and products will provide faster, easier and safer means for measuring total hemoglobin and will lead to additional device sales, and risks related to our assumptions that Rainbow measurements will deliver a sufficient level of clinical improvement over alternative capabilities to allow for rapid adoption of the technology, as well as other factors discussed in the "Risk Factors" section of our Annual Report on Form 10-K for the fiscal year ended January 3, 2009, filed with the Securities and Exchange Commission ("SEC") on March 4, 2009, which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update
'/>"/>
SOURCE Masimo
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
2. AARC Presentation Cites Masimo Patient SafetyNet as Key Factor in Improving Patient Outcomes and Reducing Costs in Post-Acute Care Facilities
3. Masimo Reports Third Quarter 2008 Financial Results
4. New Clinical Studies Presented at the American Society of Anesthesiology (ASA) Annual Meeting Show Masimo Technologies Provide Advanced Clinical Intelligence
5. Five New Clinical Studies Show Value of Masimo PVI & PI
6. Masimo to Report Third Quarter 2008 Financial Results on October 27, 2008
7. Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors
8. Masimo Announces Desaturation Index 3D Alarm as Standard Feature in All Radical-7 Pulse CO-Oximetry Devices
9. Masimo to Present at Goldman Sachs 29th Annual Global Healthcare Conference
10. Masimo to Present at Deutsche Bank 33rd Annual Health Care Conference
11. Masimo Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... California (PRWEB) September 19, 2014 ... and its potential to revolutionize the world has ... multinational corporations and small start-ups. The early years ... research projects largely due to the high risks ... Government budgets earmarked for this evolving technology have ...
(Date:9/19/2014)... -- An entire month is dedicated to one of the ... (CMT) – a debilitating neuromuscular disease affecting the arms, ... and foot and hand deformities. CMT affects 1 in ... a progressive disease, and over time patients lose the ... as leg braces, wheelchairs and scooters to get around. ...
(Date:9/19/2014)... SPRINGS, Florida , September 19, 2014 ... in medical technology, development of emerging drug systems and ... PBIO), Benton, Dickinson and Company (NYSE: BDX ... ), Regado Biosciences Inc. (NASDAQ: RGDO ), ... Hologic Inc. (NASDAQ: HOLX) Pressure BioSciences, Inc. ...
(Date:9/19/2014)... 19, 2014  Nektar Therapeutics (NASDAQ: ... characterizing the analgesic profiles of a series of ... agonist molecules. The preclinical research candidates were created ... The analgesic properties of kappa receptor ... 1,2 Kappa opioid receptors are expressed in ...
Breaking Biology Technology:Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 2Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 3Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 4Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 5Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 6Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 7Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5
... toward large-scale production -SWIFTWATER, Pa. and LYON, France, May ... sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY ... A(H1N1) seed virus, enabling the world,s leading manufacturer of ... A(H1N1) vaccine. The emergence of a new influenza A(H1N1) ...
... CA, May 27, 2009 Senomyx, Inc. (Nasdaq: ... proprietary technologies to discover and develop novel flavor ingredients ... today the appointment of David L. Linemeyer, Ph.D., to ... than 20 years of experience in directing biology research ...
... atherosclerosis vaccine,development program by AFFiRiS AG is receiving ... project is being carried out in,cooperation with German ... is to increase the amount of "good" high ... reduce the occurrence of,harmful fatty deposits in the ...
Cached Biology Technology:Sanofi Pasteur Receives Seed Virus to Produce New Influenza A(H1N1) Vaccine 2Sanofi Pasteur Receives Seed Virus to Produce New Influenza A(H1N1) Vaccine 3SENOMYX ANNOUNCES APPOINTMENT OF DAVID L. LINEMEYER, PH.D., AS VICE PRESIDENT, BIOLOGY 2SENOMYX ANNOUNCES APPOINTMENT OF DAVID L. LINEMEYER, PH.D., AS VICE PRESIDENT, BIOLOGY 3AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support 2AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support 3
(Date:9/19/2014)... sense of fairness did not evolve for the sake ... the benefits of continued cooperation, so say Frans de ... review article about inequity aversion (IA), which is defined ... is published in Science . , Their ... IA-related studies to address their hypothesis that it is ...
(Date:9/19/2014)... which over thousands of years has adapted to the arctic ... makes the cold dangerous for you. , This is happening ... the cold provoking substance, called nonylphenol, comes from the use ... of being a endocrine disruptor, but when entering the worm ... to protect the cells in its body from cold damage. ...
(Date:9/19/2014)... Conn. , Sept. 19, 2014 Nxt-ID, Inc. (Nasdaq: ... biometric authentication company focused on the growing m-commerce market, updates the ... world champion in the lightweight and light middleweight weight classes, ... Yesterday it was announced that Game of Thrones actor ... Married with Children star Katey Sagal have ...
Breaking Biology News(10 mins):Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 2NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 3
... While testing a new drug designed to treat chronic ... could identify which patients would receive maximum benefit from ... the online edition of Blood , a weekly ... Chronic lymphocytic leukemia (CLL), a cancer of ...
... three types of cells derived from human embryonic stem cells ... but are much more developmentally immature than previously thought when ... tissue. The researchers, from the Eli and Edythe Broad ... found that the progeny of the human embryonic stem cells ...
... its kind, researchers have used tools of paleontology to gain ... have shown that during the evolution of these compounds nature ... to synthesise forms, giving pointers that will help in the ... record has allowed the study of the evolution of the ...
Cached Biology News:Cells derived from pluripotent stem cells are developmentally immature 2Cells derived from pluripotent stem cells are developmentally immature 3Nature reaches for the high-hanging fruit 2